Mutated gene sparks drug race Gina Kolata

Updated: 2013-07-21 08:24

(The New York Times)

  Print Mail Large Medium  Small

 Mutated gene sparks drug race Gina Kolata

Amgen, one of three companies pursuing a drug that may lower cholesterol dramatically, has set up a factory to produce it. Christopher Capozziello for The New York Times

Mutated gene sparks drug race Gina Kolata

She was a 32-year-old aerobics instructor from a Texas suburb - healthy, college educated, with two young children. Nothing out of the ordinary, except one thing. Her cholesterol was astoundingly low. Her low-density lipoprotein, or LDL, the form that promotes heart disease, was 14, a level unheard-of in healthy adults, whose normal level is over 100.

The reason was a rare gene mutation she had inherited from both her mother and her father. Only one other person, a young, healthy Zimbabwean woman whose LDL cholesterol was 15, has ever been found with the same mutation.

The discovery has set off one of the greatest medical chases ever. It is a fevered race among three pharmaceutical companies - Amgen and Pfizer, two American companies, and Sanofi, which is French - to test and win approval for a drug that mimics the effects of the mutation, drives LDL levels to new lows and prevents heart attacks. All three companies have drugs in clinical trials and report that their results, so far, are exciting.

"This is our top priority," said Dr. Andrew Plump of Sanofi. "Nothing else we are doing has the same public health impact."

Dr. Gary H. Gibbons, the director of the United States National Heart, Lung, and Blood Institute, estimates that even if the drugs were expensive and injected, as many as two million Americans might be candidates. If the drugs could be made affordable and in pill form - two very big ifs - they might be used by one in four adults.

Heart disease remains the leading killer of Americans, causing nearly 600,000 deaths a year. Statins, the cholesterol-lowering drugs that went on the market in 1987, were a huge breakthrough, but were far from a panacea.

The companies and many heart researchers hope they are closing in on a breakthrough, cheered by success with preliminary studies. But Dr. Gibbons cautioned that critical large-scale studies that would tell whether the drugs actually prevent heart attacks are only starting. "That will show if they are a game changer," he said.

So far, people with stubbornly high cholesterol levels who are taking the drugs in preliminary studies have seen their LDL levels plunging from levels well over 100 to 50, 40, or even lower.

Dr. Barry Gumbiner, who is directing Pfizer's studies, said the company had to decide whether to set a floor for patients' LDL levels. Pfizer is interrupting treatment when LDL levels reach 25 or lower. The people seemed fine, but the company got nervous.

"There is not a lot of experience treating people to LDL levels this low," Dr. Gumbiner said.

There is another concern: cost. Each company's drug is a biologic, made in living cells at an enormous expense, like some new cancer drugs that are already straining the medical system.

Insurers generally pay for drugs approved by the United States Food and Drug Administration, and the number who might benefit from these cholesterol drugs dwarfs those who are helped by the biologic cancer drugs.

And, if the drugs come into use, researchers are asking, can cholesterol go too low?

The data point to increasing benefits with lower and lower LDL levels, said Dr. Daniel J. Rader, a cholesterol researcher at the University of Pennsylvania and a consultant for Sanofi.

Several years back, Jonathan C. Cohen and Dr. Helen H. Hobbs of the University of Texas Southwestern Medical Center in Dallas had an idea. If a mutation in a gene called PCSK9 slows the body's ability to get rid of cholesterol and leads to high LDL levels, perhaps there were defects that did the opposite - led to very low levels of LDL and protected against heart disease.

They found data from a United States study showing that some people with a single mutated PCSK9 gene that no longer functioned had somewhat lower LDL levels than normal.

Scientists began to search for people who had a mutated gene from both parents. Dr. Cohen and Dr. Hobbs found one such couple and tested their daughter in 2006. She was the aerobics instructor.

Around the same time, South African researchers began their own search and found a healthy woman at a clinic in Zimbabwe.

Those two young women showed that people could be healthy and thrive with very low LDL cholesterol levels, and seem almost immune to heart disease.

The companies want to be ready with large quantities of their versions of the drug if they are approved.

As their factories were starting to produce the drugs, the companies began recruiting patients with high LDL levels to receive the experimental substance.

David Mayse, 60, who lives in South Point, Ohio, was 49 when he had his first heart attack. Cholesterol-lowering drugs were not helping. Then Mr. Mayse had another heart attack and bypass surgery. A cardiologist who called his cholesterol levels "outrageous" asked Mr. Mayse if he would enter a clinical trial.

"I was willing to try anything at that point," Mr. Mayse said.

Mr. Mayse enrolled in a study for Amgen's experimental drug. His LDL fell to 42, from a high of 160.

The New York Times

(China Daily 07/21/2013 page9)

主站蜘蛛池模板: 黄色毛片视频在线观看| 一本色道久久88精品综合| 1a级毛片免费观看| 搡女人真爽免费影院| 亚洲欧美另类第一页| 欧美jizz18性欧美| 成年日韩片av在线网站| 亚洲国产成人久久一区久久 | 欧美日韩国产在线人成| 喝乖女的奶水h1v| 99热这里有精品| 无码日韩精品一区二区免费| 亚洲另类自拍丝袜第五页| 91久久打屁股调教网站| 成在线人永久免费视频播放| 亚洲人成在线播放网站| 男人边吃奶边激烈摸下面的视频| 国产亚洲成归v人片在线观看 | av2021天堂网手机版| 欧美一级免费看| 伊人久久大香线蕉无码| 色婷婷久久综合中文久久一本`| 天天操夜夜操免费视频| 久久丝袜精品综合网站| 欧美jizzhd极品欧美欧美xxxx18动漫| 交换韩国伦理片| 精品无码综合一区二区三区| 国产又黄又爽又猛的免费视频播放| 一级毛片在线免费视频| 欧美成人免费一区二区| 国产三级在线视频播放线| 99精品国产在热久久无码| 撒尿bbwbbw| 久久精品电影免费动漫| 欧美成人三级一区二区在线观看| 你懂得视频在线观看| 美女的尿口免费| 国产人妖视频一区二区破除| 欧美在线精品永久免费播放| 国产色视频免费| 丰满多毛的陰户视频|